MyoStrain CMR for the Detection of Cardiotoxicity (Prefect)
Prefect Study of MyoStrain CMR for the Detection of Cardiotoxicity
Sponsor: Myocardial Solutions
This observational or N/A phase trial investigates Cardiotoxicity and Chemotherapeutic Toxicity and is currently completed. Myocardial Solutions leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Sep 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Sep 2021 [monthly]
Completed
-
Oct 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Feb 2020 — Oct 2020 [monthly]
Active Not Recruiting
-
Jan 2019 — Feb 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Recruiting
-
Jul 2018 — Oct 2018 [monthly]
Recruiting
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Myocardial Solutions
For direct contact, visit the study record on ClinicalTrials.gov .